Epidemic Clostridium difficile

Medical Journal of Australia

Volumn 185, Issue 3, 2006, Pages 133-134

  Riley, Thomas V ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL CHROMOSOME; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE SEVERITY; DRUG EXPOSURE; EDITORIAL; EPIDEMIC; GENE DELETION; GENE LOCUS; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RISK; MORTALITY; NONHUMAN; RISK FACTOR;

EID: 33747586957     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00497.x     Document Type: Editorial

References (17)

1. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
2. McEllistrem MC, Carman RJ, Gerding DN, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005; 40: 265-272.
3. Kuijper Ed J, van den Berg RJ, Debast S, et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006; 12: 827-830.
4. Pépin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-472.
5. Eggertson L. C. difficile: by the numbers. CMAJ 2004; 171: 1331-1332. Erratum in: CMAJ 2005; 172: 19.
6. Riley TV. Nosocomial diarrhoea due to Clostridium difficile. Curr Opin Infect Dis 2004; 17: 323-327.
7. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005; 54 (Pt 2): 181-185.
8. Geric B, Carman RJ, Rupnik M, et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006; 193: 1143-1150.
9. Warny M, Pépin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficde associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084.
10. Pépin J, Saheb N, Coulombe M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
11. Ackermann G, Tang-Feldman YJ, Schaumann R, et al. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin Microbiol Infect 2003; 9: 526-530.
12. Golledge CL, Carson CF, O'Neil GL, et al. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1992; 30: 141-148.
13. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415.
14. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995.
15. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1201-1205.
16. Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile-associated diarrhoea: epidemiological data from Western Australia following a change in antibiotic policy. Clin Infect Dis 2002; 35: 1457-1462.
17. Eggertson L. Quebec puts up $20 million for C. difficile fight. CMAJ 2005; 172: 622.